SCHEDULE: RA Capital Maintains 9.9% Stake in Palisade Bio

RA Capital Management and its principals report a 9.9% beneficial ownership stake in Palisade Bio, Inc. as of March 31, 2026.

Summary

• RA Capital Management, L.P., along with Peter Kolchinsky and Rajeev Shah, disclosed a 9.9% beneficial ownership stake in Palisade Bio, Inc.
• The holdings consist of 7,124,116 shares of common stock and pre-funded warrants exercisable for up to 16,614,285 shares.
• The reporting persons are subject to a 9.99% beneficial ownership blocker, limiting their ability to exercise warrants beyond that threshold.
• RA Capital serves as the investment adviser for the fund and holds sole power to vote and dispose of the securities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory filing reflecting existing institutional positioning rather than a new strategic development.

Positives

• Institutional backing from a specialized healthcare investment firm, RA Capital Management.
• Clear disclosure of ownership structure and voting power delegation.

Negatives

• The 9.99% ownership blocker limits the immediate conversion of warrants into common stock, capping the reporting persons' current influence.
• The filing indicates a passive investment stance, explicitly stating the securities were not acquired for the purpose of changing or influencing control.

Risks

• Potential dilution for existing shareholders if the pre-funded warrants are fully exercised, subject to the ownership blocker.
• Reliance on the issuer's reported outstanding share count for calculating ownership percentages.

Future Outlook

The reporting persons maintain a passive investment position and do not indicate plans to change or influence the control of the issuer.

Management Comments

• The reporting persons expressly disclaim status as a group for purposes of this Schedule 13G/A.
• The filing shall not be deemed an admission that the reporting persons are the beneficial owners of such securities for any purpose other than Section 13(d) obligations.

Industry Context

StockSavvy.ai notes that institutional filings from specialized healthcare funds like RA Capital are standard in the biotech sector, often signaling long-term conviction in a company's clinical pipeline despite the passive nature of the disclosure.

Comparison to Industry Standards

• The use of 9.99% ownership blockers is a standard practice for institutional investors in small-cap biotech to avoid triggering change-of-control provisions or regulatory hurdles.
• The filing follows standard SEC disclosure requirements for institutional investment managers.

Stakeholder Impact

• Shareholders should note the significant potential dilution from the 16.6 million pre-funded warrants if the ownership blocker is adjusted or removed.

Next Steps

• Continued monitoring of the issuer's share count and potential warrant exercise activity.

Key Dates

Keywords

Palisade Bio, RA Capital, Schedule 13G, Beneficial Ownership, Biotech Investment, Pre-funded Warrants